Genfit

Focus: Genfit is a French biotechnology company focused on drug discovery across gastroenterology, infectious diseases, metabolic diseases, nephrology, and oncology. The company operates as a mid-stage biotech with a diversified pipeline primarily targeting liver and metabolic disorders.

Gastroenterology Infectious Diseases Metabolic Diseases Nephrology

Profile data last refreshed 1h ago · AI intelligence enriched 2w ago

Open Jobs

About Genfit

AI assessmentNot Hiring

No open roles listed right now. Follow Genfit to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

elafibranor

Drug-drug Interaction

Phase 1

Clinical Trials (1)

NCT03985969Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Phase 1

Help build intelligence for Genfit

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline diversity across 5 therapeutic areas with 22 active programs in Phase 1-3, providing exposure to multiple disease modalities and career development paths
Focus on high-unmet-need areas like NASH and primary biliary cholangitis, where successful candidates could impact meaningful patient populations
European-based biotech with potential for international development experience and partnership opportunities

Watch Out For

Currently zero active job openings despite active clinical portfolio, suggesting limited near-term hiring or potential organizational constraints
No marketed products and only one Phase 3 program (Elafibranor for NASH with fibrosis), indicating pre-revenue status and extended cash burn runway
Missing financial and employee count data raises transparency concerns about company stability and growth trajectory

Generated by Claude from Genfit's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Elafibranor

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT03765671Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1

Nitazoxanide

Renal Impairment

Phase 1

Clinical Trials (1)

NCT05368935Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Phase 1

GFT505 120mg - old formulation

Type 2 Diabetes

Phase 1

Clinical Trials (1)

NCT01474161Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505

Phase 1

Single Dose G1090N

Acute-on-Chronic Liver Failure

Phase 1

Clinical Trials (1)

NCT07110441Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers

Phase 1

elafibranor

Geriatrics

Phase 1

Clinical Trials (1)

NCT04171752Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Phase 1

14C-labelled GFT505 120 mg

Healthy

Phase 1

Clinical Trials (1)

NCT02142127Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers

Phase 1

Nitazoxanide

Moderate Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT05116826Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1

Elafibranor

Renal Impairment

Phase 1

Clinical Trials (1)

NCT03844555Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Phase 1

Placebo

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02091310Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Phase 1

GNS561 + Trametinib

Cholangiocarcinoma

Phase 1/2

Clinical Trials (1)

NCT05874414Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1/2

GFT505 80mg

Atherogenic Dyslipidaemia

Phase 2

Clinical Trials (1)

NCT01271751Pilot Study With GFT505 (80mg) in Atherogenic Dyslipidaemic Patients With Abdominal Obesity

Phase 2

Elafibranor 80 mg

Primary Biliary Cholangitis (PBC)

Phase 2

Clinical Trials (1)

NCT03124108Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Phase 2

Elafibranor 80mg

Non Alcoholic Steatohepatitis

Phase 2

Clinical Trials (1)

NCT03883607Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Phase 2

elafibranor 120mg

Non-Alcoholic Fatty Liver

Phase 2

Clinical Trials (1)

NCT03953456Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Phase 2

VS-01 on top of SOC

Hepatic Encephalopathy

Phase 2

Clinical Trials (1)

NCT06987968A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy

Phase 2

GFT505 80mg

Type II Diabetes Mellitus

Phase 2

Clinical Trials (1)

NCT01261494Study With GFT505 (80mg) Versus Placebo in Patients With Type 2 Diabetes Mellitus

Phase 2

GFT505 80mg

Insulin Resistance

Phase 2

Clinical Trials (1)

NCT01271777Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity